What ScreenPoint Medical does

ScreenPoint Medical B.V. is a privately held Dutch AI healthcare company founded in 2014 as a spin-off of Radboud University Medical Center, headquartered in Nijmegen, the Netherlands, with US regional headquarters in New York and an engineering/research footprint in Copenhagen, Denmark. The company develops the Transpara Breast AI Suite, a deep-learning-based clinical decision support platform that analyzes both 2D (FFDM) and 3D (DBT) mammograms. The suite comprises three modules: Transpara Detection (which assigns per-region cancer risk on a 98-point scale and classifies exams as Elevated, Intermediate, or Low Risk, with a 99.97% negative predictive value on Low Risk exams), Transpara Density (combining BI-RADS-like composition with volumetric breast density trained on MRI ground truth), and Transpara Temporal Comparison (which analyzes findings across up to three prior mammograms, increasing Elevated/Intermediate sensitivity by up to 8% and reducing false positives by 37%).

The platform is vendor-agnostic, integrating across PACS systems (Sectra, GE), imaging OEMs (Fujifilm, Siemens Healthineers, Canon/Fomei), and AI orchestration platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Health Model Hub, Incepto, Synthesis Health, Ikonopedia, NTT Data). Transpara is FDA-cleared (K241831, K232096) and CE-marked under EU MDR (Notified Body 0344) for both 2D and 3D mammography, cleared for sale in 40 countries, and has processed more than 12 million mammograms across 30+ countries. It is the only breast AI solution included in randomized controlled trials — MASAI in Sweden (105,000+ women, results published in The Lancet showing 29% increase in cancer detection, 44% reduction in radiologist workload, and a 12% reduction in interval cancers), PRISM in the US (400,000 exams, $16M PCORI-funded), and AIMS in Norway (140,000+ women) — and is backed by 55+ peer-reviewed publications.

ScreenPoint generates revenue primarily through enterprise SaaS / multi-year subscription licenses to hospitals, academic medical centers, radiology practices, and national or regional screening programs, with pricing conducted on a quote-based, undisclosed basis. A complementary usage-based revenue stream exists where imaging-center chains resell Transpara as a paid per-study add-on (e.g., the $40 mammography AI add-on launched by Rayus Radiology at its ~150 outpatient imaging centers). Non-dilutive research grants (EFRO, Health~Holland, PCORI) supplement R&D funding. The company has raised $49M in total capital from Insight Partners and Siemens Healthineers, employs 51–100 people, and operates in customer segments including direct enterprise sales to hospital systems, channel and OEM partnerships, and public-health-system procurement. In January 2025, ScreenPoint acquired Biomediq A/S (Denmark) to expand into breast cancer risk assessment, and the company continues to publish consecutive algorithm updates (Transpara 2.1) and secure flagship integrations (Microsoft Precision Imaging Network, December 2025).

Name

ScreenPoint Medical

Legal name

ScreenPoint Medical B.V.

Website

https://screenpoint-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

ScreenPoint Medical develops the Transpara Breast AI Suite, a deep-learning platform for detecting breast cancer in 2D and 3D mammograms, serving hospitals, academic medical centers, radiology practices, and national screening programs across 30+ countries.

Ownership category

akta.pro rank

Product category

Medical Imaging AI / Breast Cancer Screening Software

NAICS

Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)

Keywords

• Breast cancer screening AI
• Mammography image analysis
• Deep learning radiology
• Clinical decision support
• Medical imaging software

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Enterprise SaaS / software subscription for Transpara Breast AI: Primary revenue stream based on licensing the Transpara Detection, Density, and Temporal Comparison modules to hospitals, academic medical centers, radiology practices, and national/regional screening programs. Quote-based pricing (not publicly disclosed) and multi-year contracts inferred from enterprise sales motion and Schedule Demo lead capture.
2. Per-study AI add-on services (e.g., $40 mammography AI add-on at Rayus Radiology): Pricing in some partner-distributed deployments is on a per-study/per-exam basis; for example, Rayus Radiology launched a $40 mammography AI add-on service using Transpara at its outpatient imaging centers.
3. Research grant and non-dilutive funding (e.g., EFRO, Health~Holland): Non-dilutive research grants from bodies such as the European Fund for Regional Development (EFRO Oost) and Health~Holland fund specific research initiatives (Autonomous AI for Cancer Detection, aiEMBRACE). These grants supplement R&D but are not core commercial revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

ScreenPoint Medical develops and licenses the Transpara Breast AI Suite — deep-learning based clinical decision-support software that analyzes 2D (FFDM) and 3D (DBT) mammograms to detect breast cancer, assess breast density, and compare findings against prior exams. The platform integrates within existing PACS and AI platforms and is sold via enterprise subscriptions and per-study licensing to hospitals, radiology practices, and national screening programs in 30+ countries.

Product overview

ScreenPoint Medical offers a single platform-plus-modules architecture built around the Transpara Breast AI Suite. The suite consists of a core module, Transpara Detection (AI breast cancer detection for 2D/3D mammography), and complementary add-on modules: Transpara Density (automated BI-RADS-like and volumetric breast density reporting) and Transpara Temporal Comparison (AI comparison against up to three prior mammograms). These modules work together to provide a 'second pair of eyes' for radiologists, delivering cancer detection, density assessment, and change-over-time analysis within existing PACS and AI platforms (e.g., Aidoc aiOS, Microsoft for Healthcare Precision Imaging Network, Ferrum Health Model Hub, and Ikonopedia). The suite is FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Transpara: Flagship Breast AI product suite from ScreenPoint Medical, including detection, density assessment, and temporal comparison capabilities for 2D and 3D mammography.
• Transpara Detection
• Transpara Density
• Transpara Temporal Comparison

Products and services

• Transpara Detection AI-driven breast cancer detection tool for 2D mammography (FFDM) and 3D mammography (DBT) that categorizes exams into Elevated, Intermediate, or Low Risk using a 98-point region risk scale; Low Risk exams have a 99.97% negative predictive value. FDA-cleared (K241831, K232096) and CE-marked under MDR; deployed in 30+ countries with 12M+ mammograms processed.
• Transpara Density Automated breast density assessment combining a BI-RADS-like composition assessment (5th Ed.) with a volumetric breast density (VBD) measurement trained against MRI ground truth. Supports MQSA Final Rule compliance in the USA and integration with the IBIS / Tyrer-Cuzick V8 risk model. Available for both FFDM and DBT.
• Transpara Temporal Comparison AI feature that tracks findings across up to three prior mammograms (9 months to 6.5 years prior), increasing the sensitivity of Elevated and Intermediate Risk Scores by up to 8% and reducing false positives by 37% at 71% sensitivity based on internal analysis and ECR 2025 research.
• Transpara Breast AI Suite Integrated suite of AI applications for the breast imaging continuum combining Transpara Detection (cancer detection), Transpara Density (breast density reporting), and Transpara Temporal Comparison (prior comparison). Designed as a vendor-agnostic decision-support layer that works within existing PACS, AI platforms (Aidoc aiOS, Microsoft Precision Imaging Network, Ferrum Model Hub), and mammography acquisition environments. FDA-cleared, CE-marked under MDR, and deployed across 30+ countries.

Quantifiable outcome

• 29% increase in cancer detection rate (MASAI RCT, 105,000+ women)
• +11 more outcomes

Named customers21 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration17 records

AI capability7 records

Feature6 records

Partnerships

18 partnerships are on record, tiered flagship, core and minor.

• Sacyl (Castilla y León regional health system, Spain)flagshipChannel Partner/ Reseller/ Distributor · 24 September 2025Partnership announced September 24, 2025 at EUSOBI 2025 to deploy Transpara Detection, Density, and Temporal Comparison across approximately 15-17 breast cancer screening centers in the Castilla y León region of Spain; serves women aged 45-74 in a Ministry of Health-run program. Sacyl selected ScreenPoint after extensive vendor comparison.
• Biomediq A/ScoreStrategic or Co-development Partner · 8 January 2025Acquired by ScreenPoint Medical on January 8, 2025 to expand breast cancer risk assessment capabilities. Biomediq A/S specializes in quantitative imaging biomarkers for breast cancer risk assessment; the acquisition enhances Transpara's risk prediction capabilities based on prior collaborative research.
• Fujifilm Healthcare AmericascoreOEM/ Whitelabel/ Licensing PartnerStrategic partnership offering Fujifilm customers Transpara as integrated clinical decision-support for women's health imaging. Fujifilm quote: 'Fujifilm is thrilled to form and expand partnerships with leading companies that share the same commitment to improve patient lives through advances in breast imaging technology.' Christine Murray is Women's Health Marketing Director at Fujifilm Healthcare Americas.
• AidocflagshipTechnology or IntegrationStrategic technology integration partner. Aidoc's aiOS platform will host Transpara as part of the PRISM RCT clinical workflow integration. Tom Valent, VP of Business Development at Aidoc, cited ScreenPoint as 'the ideal partner for Aidoc in the women's health space.'
• Microsoft (Precision Imaging Network, part of Microsoft for Healthcare)flagshipTechnology or IntegrationCommercial agreement announced December 1, 2025 making the Transpara breast-imaging AI portfolio available through Precision Imaging Network, part of Microsoft for Healthcare. Simplifies cloud-enabled access to Breast AI tools within existing clinical ecosystems. Quote from Vikram Chhabra, General Manager, Diagnostic Solutions at Microsoft.
• Ferrum HealthcoreTechnology or IntegrationPartnership announced January 2026 to offer Transpara Breast AI through Ferrum's AI Governance Suite / Model Hub. Peter Eason, COO of Ferrum Health, stated the availability on Ferrum's Model Hub reflects health systems' demand for 'proven performance, real-world scale, and trust.'
• GE HealthcarecoreTechnology or IntegrationImaging technology and PACS integration partner. Transpara integrates with GE Healthcare software offerings to deliver breast AI insights within clinical workflows.
• SectracoreTechnology or IntegrationPACS integration partner; Transpara integrates into Sectra's reading environment to deliver breast AI insights without disrupting radiologist workflow.
• IkonopediacoreTechnology or IntegrationIntegration partnership announced June 14, 2025 providing radiologists with automated AI insights for more accurate and productive patient diagnoses and care. Emily Crane is CEO & President of Ikonopedia.
• ARJ (Medical UAE)minorChannel Partner/ Reseller/ DistributorRegional distributor providing AI for breast cancer detection in the United Arab Emirates market.
• EGT (Middle East & Africa)minorChannel Partner/ Reseller/ DistributorRegional distributor covering the Middle East and Africa region.
• Answer Medical SolutionsminorChannel Partner/ Reseller/ DistributorChannel partner for distribution and deployment in regional markets.
• Fomei (Czech Republic / Canon)minorChannel Partner/ Reseller/ DistributorRegional partner covering Czech Republic and adjacent markets for breast imaging distribution.
• Medicore ConsultminorChannel Partner/ Reseller/ DistributorRegional consulting and distribution partner for Transpara deployment.
• Radboud University Medical Center (Radboudumc)flagshipStrategic or Co-development PartnerScreenPoint Medical was founded as a spin-off of Radboud University Medical Center (home of co-founder Professor Nico Karssemeijer). Active research collaborator on the EFRO 'Autonomous AI for Cancer Detection' project (with Thirona) and aiEMBRACE (with NKI, Memorial Sloan Kettering, Radboudumc). Project runtime Nov 2023 – Nov 2026.
• Netherlands Cancer Institute (NKI-AVL)coreStrategic or Co-development PartnerResearch partner in the aiEMBRACE project (Nov 2023 – Nov 2026) advancing AI-based technology to support women at elevated risk through the breast cancer patient journey. Other aiEMBRACE partners include Memorial Sloan Kettering and Radboudumc.
• Memorial Sloan Kettering Cancer Center (MSKCC)coreStrategic or Co-development PartnerResearch partner in the aiEMBRACE project developing MRI breast cancer detection algorithms, risk algorithms for future breast cancer development, cancer recurrence prediction, and treatment response monitoring.
• ThironacoreStrategic or Co-development PartnerResearch partner on the EFRO-funded 'Autonomous AI for Cancer Detection' project (Jan 2025 – End of 2027) developing AI tools for early detection of breast and lung cancer, alongside Radboud UMC and ScreenPoint Medical.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Therapixel: France-based AI mammography vendor with MammoScreen 2.0 FDA-cleared for breast cancer detection on 2D mammograms. Direct competitor to Transpara Detection in radiology practice and screening program RFPs, particularly in Europe and the US.
• Lunit: South Korean AI medical imaging company with Lunit INSIGHT MMG for mammography, FDA-cleared and CE-marked. Direct competitor to Transpara in breast cancer detection, with strong publication record and global screening program ambitions.
• iCAD (Bracco): Legacy breast AI vendor offering ProFound AI for DBT and breast density assessment, now part of Bracco's imaging business. Direct competitor across Transpara's Detection and Density modules, especially in US radiology practices.
• Volpara Health: New Zealand/US company specializing in AI-driven breast density, risk assessment, and quality assurance. Directly comparable on the Density and risk-modeling side of Transpara, with strong US mammography practice footprint.

Emerging players

• DeepHealth (RadNet): RadNet subsidiary (incorporating iCAD's breast AI assets) commercializing breast cancer detection and density AI across RadNet's ~370 imaging centers. Emerging player pursuing integrated screening program deployments comparable to Transpara.
• Densitas: Canadian AI vendor specializing in breast density, image quality, and mammography reporting analytics. Emerging player focused on a subset of Transpara's Density and quality assurance modules.

Broad incumbents

• Hologic: Major mammography OEM (3Dimensions, Genius AI) with embedded AI capabilities and a global installed base. Broad incumbent that competes via bundled hardware-AI offerings rather than standalone vendor-neutral software.
• GE HealthCare: Major imaging OEM with mammography, PACS, and AI capabilities (Edison platform). Broad incumbent and existing integration partner; could substitute Transpara with native AI in customer negotiations.
• Fujifilm Healthcare: Imaging OEM and existing Transpara partner; competes via women's health portfolio that may include bundled breast AI capabilities. Broad incumbent in DBT mammography.

Others

• Aidoc: Clinical AI platform with aiOS that hosts multi-specialty AI including Transpara for the PRISM RCT. Adjacent infrastructure partner that could either remain a partner or vertically integrate breast AI capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/screenpointmed

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScreenPoint Medical